Pre-symptomatic individuals | RA | Controls a | |
---|---|---|---|
(n = 370) | (n = 203) | (n = 585) | |
Females (%) | 81 | 77 | 71 |
Median age, years | 49.9 | 56.5 | 50.3 |
(Q1-Q3) g | (30.6–58.8) | (48.7–63.7) | (40.2–60.1) |
Ever-smoker (%) | 230/348 (66.1)*** | 136/200 (68)*** | 254/552 (46.0) |
HLA-DR SEb, n (%) | 240/366 (65.6) *** | 129/204 (63.2) *** | 229/585 (39.1) |
anti-CCP2 absc, % (95% CI) | 34.9 (30.2–39.9)*** | 74.5 (68.0–80.0)***d | 2.4 (1.4–4.0) |
anti-CEP-1/Eno5-21 abs, % (95% CI) | 28.9 (24.5–33.7)*** | 67.3 (60.5–73.5)***e | 6.1 (4.4–8.4)f |
anti-citC1359-369 abs, % (95% CI) | 13.1 (10–17.1)*** | 32.2 (26.1–39.0)***e | 4.4 (3.0–6.4)f |
anti-Fibα563-583 abs, % (95% CI) | 10.8 (8–14.4)*** | 34.2 (27.9–41.0)***e | 5.2 (3.6–7.4)f |
anti-Fibα580-600 abs, % (95% CI) | 8.7 (6.2–12.1) | 14.1 (9.9–19.7)***e | 6.1 (4.4–8.4)f |
anti-Fibß36-52 abs, % (95% CI) | 29.7 (25.3–34.6)*** | 64.8 (58.0–71.1)***e | 6.6 (4.9–9.0)f |
anti-Fibß62-81a (72) abs, % (95% CI) | 11.6 (8.7–15.3)*** | 14.6 (10.3–20.2)***e | 3.1 (2.0–5.0)f |
anti-Fibß62-81b (74) abs, % (95% CI) | 15.9 (12.5–20.1)*** | 34.2 (27.9–41.0)***e | 1.7 (0.9–3.2)f |
anti-CCP-1/Fil307-324 abs, % (95% CI) | 26.2 (22–30.9)*** | 46.2 (39.4–53.2)***e | 3.0 (1.8–4.7)f |
anti-Vim60-75 abs, % (95% CI) | 13.0 (9.9–16.8)*** | 29.1 (23.3–35.8)***e | 5.4 (3.8–7.6)f |
anti-Vim2-17 abs, % (95% CI) | 7.0 (4.8–10.2)* | 11.1 (7.4–16.3)***e | 3.8 (2.5–5.8)f |